LINK . SPRINGER . COM {}

Matching Content Categories {📚}

• Education
• Health & Fitness
• Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

patients, arm, study, gedatolisib, cancer, combination, article, grade, irinotecan, dose, pubmed, treatment, aes, inhibitor, table, google, scholar, phase, advanced, cas, pik, activity, inhibitors, arms, solid, clinical, patient, mek, tumors, antitumor, pikmtor, cycle, safety, treatmentrelated, supplementary, clin, due, day, plasma, oncol, similar, combinations, response, colorectal, kras, mutations, kinase, tumor, bid, doseescalation,

Topics {✒️}

triple-negative breast cancer mitogen-activated protein kinase matched targeted therapy treatment-related adverse events ras-raf-mek-erk terminal half-life ranged investigational anticancer therapy advanced/metastatic solid tumor targeted therapies pi3k/akt/mtor inhibitors [25 pi3k/akt/mtor inhibitors pi3k/mtor inhibitor gsk2126458 early-phase clinical trials article download pdf plasma concentration–time profile pi3k/akt/mtor pathway common treatment-related aes pan-pi3k inhibitors effects gianluca del conte kras-mutated ovarian cancer inhibiting tumor growth prior phase ii results irinotecan-refractory colorectal cancer kras/braf mutation status dose-limiting toxicity [dlt] multicenter phase ii received irinotecan therapy metastatic colorectal cancer del conte declare pi3k/mtor inhibitor pf-5212384 open-label study pi3k/mtor inhibitors pf-04691502 dose-escalation groups/stage 1 early-phase trials mucosal inflammation/stomatitis common aes related phase ib study privacy choices/manage cookies britten received support advanced colorectal cancer early clinical trials irinotecan-based therapies full size image potent dual inhibitor maximum plasma concentration dose-limiting toxicity 4 dose-limiting toxicity mek inhibitor trametinib full size table common terminology criteria

Schema {🗺️}

WebPage:
      mainEntity:
         headline:A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
         description:This phase I, four-arm, open-label study (NCT01347866) evaluated the PI3K/mTOR inhibitors PF-04691502 (arms A, B) and gedatolisib (PF-05212384; arms C, D) in combination with the MEK inhibitor PD-0325901 (arm A, D) or irinotecan (arm B, C) in patients with advanced solid tumors. Primary endpoint was dose-limiting toxicity with each combination. Secondary endpoints included safety, pharmacokinetics and preliminary antitumor activity. Dose escalation followed a 3 + 3 design in arm C and a zone-based design in arm D. The PF-04691502 combination arms were closed prematurely due to low tolerability, and the maximum tolerated doses (MTDs) were not determined for either arm. The MTD for the combination of gedatolisib with irinotecan 180 mg/m2 was estimated to be 110 mg weekly and for the combination with PD-0325901 was not reached at the highest dose evaluated (gedatolisib 154 mg weekly). Plasma concentrations of gedatolisib were generally similar across dose groups in arm C (with irinotecan) and arm D (with PD-0325901). Frequent dose delays or dose reductions were required for both combinations, potentially preventing sustained therapeutic drug concentrations. Gedatolisib plus irinotecan produced a response rate of ~5% and clinical benefit in 16% of patients with advanced colorectal cancer (progression-free survival, 2.8 months). Preliminary evidence of clinical activity was observed with gedatolisib plus PD-0325901 in patients with ovarian cancer (three partial responses, n = 5) or endometrial cancer (one partial response, n = 1) and KRAS mutations. Further evaluations of gedatolisib are warranted in patients with advanced solid malignancies.
         datePublished:2017-10-24T00:00:00Z
         dateModified:2017-10-24T00:00:00Z
         pageStart:775
         pageEnd:785
         sameAs:https://doi.org/10.1007/s11523-017-0530-5
         keywords:
            Oncology
            Biomedicine
            general
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-017-0530-5/MediaObjects/11523_2017_530_Figa_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-017-0530-5/MediaObjects/11523_2017_530_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-017-0530-5/MediaObjects/11523_2017_530_Fig2_HTML.gif
         isPartOf:
            name:Targeted Oncology
            issn:
               1776-260X
               1776-2596
            volumeNumber:12
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Zev A. Wainberg
               affiliation:
                     name:David Geffen School of Medicine at UCLA
                     address:
                        name:David Geffen School of Medicine at UCLA, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Maria Alsina
               affiliation:
                     name:Universitat Autònoma de Barcelona
                     address:
                        name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Heloisa P. Soares
               affiliation:
                     name:Moffitt Cancer Center
                     address:
                        name:Moffitt Cancer Center, Tampa, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Irene Braña
               affiliation:
                     name:Princess Margaret Cancer Centre
                     address:
                        name:Princess Margaret Cancer Centre, Toronto, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Carolyn D. Britten
               affiliation:
                     name:Medical University of South Carolina
                     address:
                        name:Medical University of South Carolina, Charleston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gianluca Del Conte
               affiliation:
                     name:IRCCS Ospedale S. Raffaele
                     address:
                        name:IRCCS Ospedale S. Raffaele, Milan, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Patrick Ezeh
               affiliation:
                     name:Pfizer Oncology
                     address:
                        name:Pfizer Oncology, Cambridge, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Brett Houk
               affiliation:
                     name:Pfizer Oncology
                     address:
                        name:Pfizer Oncology, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kenneth A. Kern
               affiliation:
                     name:Pfizer Oncology
                     address:
                        name:Pfizer Oncology, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Stephen Leong
               affiliation:
                     name:University of Colorado Denver School of Medicine
                     address:
                        name:University of Colorado Denver School of Medicine, Aurora, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Nuzhat Pathan
               affiliation:
                     name:Pfizer Oncology
                     address:
                        name:Pfizer Oncology, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kristen J. Pierce
               affiliation:
                     name:Pfizer Oncology
                     address:
                        name:Pfizer Oncology, Groton, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lillian L. Siu
               affiliation:
                     name:Princess Margaret Cancer Centre
                     address:
                        name:Princess Margaret Cancer Centre, Toronto, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jennifer Vermette
               affiliation:
                     name:Pfizer Oncology
                     address:
                        name:Pfizer Oncology, Cambridge, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Josep Tabernero
               affiliation:
                     name:Universitat Autònoma de Barcelona
                     address:
                        name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
      description:This phase I, four-arm, open-label study (NCT01347866) evaluated the PI3K/mTOR inhibitors PF-04691502 (arms A, B) and gedatolisib (PF-05212384; arms C, D) in combination with the MEK inhibitor PD-0325901 (arm A, D) or irinotecan (arm B, C) in patients with advanced solid tumors. Primary endpoint was dose-limiting toxicity with each combination. Secondary endpoints included safety, pharmacokinetics and preliminary antitumor activity. Dose escalation followed a 3 + 3 design in arm C and a zone-based design in arm D. The PF-04691502 combination arms were closed prematurely due to low tolerability, and the maximum tolerated doses (MTDs) were not determined for either arm. The MTD for the combination of gedatolisib with irinotecan 180 mg/m2 was estimated to be 110 mg weekly and for the combination with PD-0325901 was not reached at the highest dose evaluated (gedatolisib 154 mg weekly). Plasma concentrations of gedatolisib were generally similar across dose groups in arm C (with irinotecan) and arm D (with PD-0325901). Frequent dose delays or dose reductions were required for both combinations, potentially preventing sustained therapeutic drug concentrations. Gedatolisib plus irinotecan produced a response rate of ~5% and clinical benefit in 16% of patients with advanced colorectal cancer (progression-free survival, 2.8 months). Preliminary evidence of clinical activity was observed with gedatolisib plus PD-0325901 in patients with ovarian cancer (three partial responses, n = 5) or endometrial cancer (one partial response, n = 1) and KRAS mutations. Further evaluations of gedatolisib are warranted in patients with advanced solid malignancies.
      datePublished:2017-10-24T00:00:00Z
      dateModified:2017-10-24T00:00:00Z
      pageStart:775
      pageEnd:785
      sameAs:https://doi.org/10.1007/s11523-017-0530-5
      keywords:
         Oncology
         Biomedicine
         general
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-017-0530-5/MediaObjects/11523_2017_530_Figa_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-017-0530-5/MediaObjects/11523_2017_530_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-017-0530-5/MediaObjects/11523_2017_530_Fig2_HTML.gif
      isPartOf:
         name:Targeted Oncology
         issn:
            1776-260X
            1776-2596
         volumeNumber:12
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Zev A. Wainberg
            affiliation:
                  name:David Geffen School of Medicine at UCLA
                  address:
                     name:David Geffen School of Medicine at UCLA, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Maria Alsina
            affiliation:
                  name:Universitat Autònoma de Barcelona
                  address:
                     name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Heloisa P. Soares
            affiliation:
                  name:Moffitt Cancer Center
                  address:
                     name:Moffitt Cancer Center, Tampa, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Irene Braña
            affiliation:
                  name:Princess Margaret Cancer Centre
                  address:
                     name:Princess Margaret Cancer Centre, Toronto, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Carolyn D. Britten
            affiliation:
                  name:Medical University of South Carolina
                  address:
                     name:Medical University of South Carolina, Charleston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gianluca Del Conte
            affiliation:
                  name:IRCCS Ospedale S. Raffaele
                  address:
                     name:IRCCS Ospedale S. Raffaele, Milan, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Patrick Ezeh
            affiliation:
                  name:Pfizer Oncology
                  address:
                     name:Pfizer Oncology, Cambridge, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Brett Houk
            affiliation:
                  name:Pfizer Oncology
                  address:
                     name:Pfizer Oncology, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kenneth A. Kern
            affiliation:
                  name:Pfizer Oncology
                  address:
                     name:Pfizer Oncology, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Stephen Leong
            affiliation:
                  name:University of Colorado Denver School of Medicine
                  address:
                     name:University of Colorado Denver School of Medicine, Aurora, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Nuzhat Pathan
            affiliation:
                  name:Pfizer Oncology
                  address:
                     name:Pfizer Oncology, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kristen J. Pierce
            affiliation:
                  name:Pfizer Oncology
                  address:
                     name:Pfizer Oncology, Groton, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lillian L. Siu
            affiliation:
                  name:Princess Margaret Cancer Centre
                  address:
                     name:Princess Margaret Cancer Centre, Toronto, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jennifer Vermette
            affiliation:
                  name:Pfizer Oncology
                  address:
                     name:Pfizer Oncology, Cambridge, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Josep Tabernero
            affiliation:
                  name:Universitat Autònoma de Barcelona
                  address:
                     name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Targeted Oncology
      issn:
         1776-260X
         1776-2596
      volumeNumber:12
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:David Geffen School of Medicine at UCLA
      address:
         name:David Geffen School of Medicine at UCLA, Los Angeles, USA
         type:PostalAddress
      name:Universitat Autònoma de Barcelona
      address:
         name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
         type:PostalAddress
      name:Moffitt Cancer Center
      address:
         name:Moffitt Cancer Center, Tampa, USA
         type:PostalAddress
      name:Princess Margaret Cancer Centre
      address:
         name:Princess Margaret Cancer Centre, Toronto, Canada
         type:PostalAddress
      name:Medical University of South Carolina
      address:
         name:Medical University of South Carolina, Charleston, USA
         type:PostalAddress
      name:IRCCS Ospedale S. Raffaele
      address:
         name:IRCCS Ospedale S. Raffaele, Milan, Italy
         type:PostalAddress
      name:Pfizer Oncology
      address:
         name:Pfizer Oncology, Cambridge, USA
         type:PostalAddress
      name:Pfizer Oncology
      address:
         name:Pfizer Oncology, San Diego, USA
         type:PostalAddress
      name:Pfizer Oncology
      address:
         name:Pfizer Oncology, San Diego, USA
         type:PostalAddress
      name:University of Colorado Denver School of Medicine
      address:
         name:University of Colorado Denver School of Medicine, Aurora, USA
         type:PostalAddress
      name:Pfizer Oncology
      address:
         name:Pfizer Oncology, San Diego, USA
         type:PostalAddress
      name:Pfizer Oncology
      address:
         name:Pfizer Oncology, Groton, USA
         type:PostalAddress
      name:Princess Margaret Cancer Centre
      address:
         name:Princess Margaret Cancer Centre, Toronto, Canada
         type:PostalAddress
      name:Pfizer Oncology
      address:
         name:Pfizer Oncology, Cambridge, USA
         type:PostalAddress
      name:Universitat Autònoma de Barcelona
      address:
         name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Zev A. Wainberg
      affiliation:
            name:David Geffen School of Medicine at UCLA
            address:
               name:David Geffen School of Medicine at UCLA, Los Angeles, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Maria Alsina
      affiliation:
            name:Universitat Autònoma de Barcelona
            address:
               name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
               type:PostalAddress
            type:Organization
      name:Heloisa P. Soares
      affiliation:
            name:Moffitt Cancer Center
            address:
               name:Moffitt Cancer Center, Tampa, USA
               type:PostalAddress
            type:Organization
      name:Irene Braña
      affiliation:
            name:Princess Margaret Cancer Centre
            address:
               name:Princess Margaret Cancer Centre, Toronto, Canada
               type:PostalAddress
            type:Organization
      name:Carolyn D. Britten
      affiliation:
            name:Medical University of South Carolina
            address:
               name:Medical University of South Carolina, Charleston, USA
               type:PostalAddress
            type:Organization
      name:Gianluca Del Conte
      affiliation:
            name:IRCCS Ospedale S. Raffaele
            address:
               name:IRCCS Ospedale S. Raffaele, Milan, Italy
               type:PostalAddress
            type:Organization
      name:Patrick Ezeh
      affiliation:
            name:Pfizer Oncology
            address:
               name:Pfizer Oncology, Cambridge, USA
               type:PostalAddress
            type:Organization
      name:Brett Houk
      affiliation:
            name:Pfizer Oncology
            address:
               name:Pfizer Oncology, San Diego, USA
               type:PostalAddress
            type:Organization
      name:Kenneth A. Kern
      affiliation:
            name:Pfizer Oncology
            address:
               name:Pfizer Oncology, San Diego, USA
               type:PostalAddress
            type:Organization
      name:Stephen Leong
      affiliation:
            name:University of Colorado Denver School of Medicine
            address:
               name:University of Colorado Denver School of Medicine, Aurora, USA
               type:PostalAddress
            type:Organization
      name:Nuzhat Pathan
      affiliation:
            name:Pfizer Oncology
            address:
               name:Pfizer Oncology, San Diego, USA
               type:PostalAddress
            type:Organization
      name:Kristen J. Pierce
      affiliation:
            name:Pfizer Oncology
            address:
               name:Pfizer Oncology, Groton, USA
               type:PostalAddress
            type:Organization
      name:Lillian L. Siu
      affiliation:
            name:Princess Margaret Cancer Centre
            address:
               name:Princess Margaret Cancer Centre, Toronto, Canada
               type:PostalAddress
            type:Organization
      name:Jennifer Vermette
      affiliation:
            name:Pfizer Oncology
            address:
               name:Pfizer Oncology, Cambridge, USA
               type:PostalAddress
            type:Organization
      name:Josep Tabernero
      affiliation:
            name:Universitat Autònoma de Barcelona
            address:
               name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
               type:PostalAddress
            type:Organization
PostalAddress:
      name:David Geffen School of Medicine at UCLA, Los Angeles, USA
      name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
      name:Moffitt Cancer Center, Tampa, USA
      name:Princess Margaret Cancer Centre, Toronto, Canada
      name:Medical University of South Carolina, Charleston, USA
      name:IRCCS Ospedale S. Raffaele, Milan, Italy
      name:Pfizer Oncology, Cambridge, USA
      name:Pfizer Oncology, San Diego, USA
      name:Pfizer Oncology, San Diego, USA
      name:University of Colorado Denver School of Medicine, Aurora, USA
      name:Pfizer Oncology, San Diego, USA
      name:Pfizer Oncology, Groton, USA
      name:Princess Margaret Cancer Centre, Toronto, Canada
      name:Pfizer Oncology, Cambridge, USA
      name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain

External Links {🔗}(145)

• How much revenue does https://www.springernature.com/gp/authors bring in?
• What's https://link.springernature.com/home/'s gross income?
• How much profit is https://order.springer.com/public/cart making per month?
• What's the financial gain of https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research?
• https://www.editorialmanager.com/targ's total income per month
• What's the income generated by https://beta.springernature.com/pre-submission?journalId=11523 each month?
• How much does http://clinicaltrials.gov bring in each month?
• Get to know https://doi.org/10.1200%2FJCO.2009.25.3641's earnings
• What are the total earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20085938?
• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834432's total income per month
• What's the income generated by http://scholar.google.com/scholar_lookup?&title=The%20PI3K%20pathway%20as%20drug%20target%20in%20human%20cancer&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2009.25.3641&volume=28&issue=6&pages=1075-1083&publication_year=2010&author=Courtney%2CKD&author=Corcoran%2CRB&author=Engelman%2CJA each month?
• What's the financial outcome of https://doi.org/10.1038%2Fsj.onc.1210422?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17496923 generate monthly?
• http://scholar.google.com/scholar_lookup?&title=Targeting%20the%20Raf-MEK-ERK%20mitogen%20activated%20protein%20kinase%20cascade%20for%20the%20treatment%20of%20cancer&journal=Oncogene&doi=10.1038%2Fsj.onc.1210422&volume=26&issue=22&pages=3291-3310&publication_year=2007&author=Roberts%2CP&author=Der%2CC's total income per month
• How much does https://doi.org/10.1016%2Fj.jmoldx.2010.11.005 gross monthly?
• What's the monthly income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21227396?
• How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070595 rake in every month?
• Earnings of http://scholar.google.com/scholar_lookup?&title=Detection%20of%20KRAS%20and%20BRAF%20mutations%20in%20colorectal%20carcinoma.%20Roles%20for%20high-sensitivity%20locked%20nucleic%20acid-PCR%20sequencing%20and%20broad-spectrum%20mass%20spectrometry%20genotyping&journal=J%20Mol%20Diagn&doi=10.1016%2Fj.jmoldx.2010.11.005&volume=13&issue=1&pages=64-73&publication_year=2011&author=Arcila%2CM&author=Lau%2CC&author=Nafa%2CK&author=Ladanyi%2CM
• How much does https://doi.org/10.1093%2Fannonc%2Fmdp347 generate monthly?
• How much income does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19713247 have?
• Revenue of http://scholar.google.com/scholar_lookup?&title=Status%20of%20PI3K%20inhibition%20and%20biomarker%20development%20in%20cancer%20therapeutics&journal=Ann%20Oncol&doi=10.1093%2Fannonc%2Fmdp347&volume=21&issue=4&pages=683-691&publication_year=2010&author=Markman%2CB&author=Atzori%2CF&author=P%C3%A9rez-Garc%C3%ADa%2CJ&author=Tabernero%2CJ&author=Baselga%2CJ
• See how much https://doi.org/10.1016%2Fj.tibs.2011.03.006 makes per month
• What's the monthly income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21531565?
• How much profit does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112285 generate?
• Revenue of http://scholar.google.com/scholar_lookup?&title=The%20RAS-Erk%20and%20PI3K-mTOR%20pathways%3A%20cross-talk%20and%20compensation&journal=Trends%20Biochem%20Sci&doi=10.1016%2Fj.tibs.2011.03.006&volume=36&issue=6&pages=320-328&publication_year=2011&author=Mendoza%2CMM&author=Er%2CEE&author=Blenis%2CJ
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23232172 income
• Learn about the earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552942
• How much does http://scholar.google.com/scholar_lookup?&title=Clinical%20development%20of%20phosphatidylinositol%203-kinase%20inhibitors%20for%20cancer%20treatment&journal=BMC%20Med&doi=10.1186%2F1741-7015-10-161&volume=10&pages=161-176&publication_year=2012&author=Bra%C3%B1a%2CI&author=Siu%2CLL gross monthly?
• How much money does https://doi.org/10.1038%2Fnrclinonc.2013.10 generate?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23400000 bring in each month?
• http://scholar.google.com/scholar_lookup?&title=Development%20of%20PI3K%20inhibitors%3A%20lessons%20learned%20from%20early%20clinical%20trials&journal=Nat%20Rev%20Clin%20Oncol&doi=10.1038%2Fnrclinonc.2013.10&volume=10&issue=3&pages=143-153&publication_year=2013&author=Rodon%2CJ&author=Dienstmann%2CR&author=Serra%2CV&author=Tabernero%2CJ's financial summary
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22684718 net monthly?
• How much income is http://scholar.google.com/scholar_lookup?&title=Combination%20of%20a%20MEK%20inhibitor%20at%20sub-MTD%20with%20a%20PI3K%2FmTOR%20inhibitor%20significantly%20suppresses%20growth%20of%20lung%20adenocarcinoma%20tumors%20in%20Kras%28G12D-LSL%29%20mice&journal=Cancer%20Chemother%20Pharmacol&doi=10.1007%2Fs00280-012-1899-6&volume=70&issue=2&pages=213-220&publication_year=2012&author=Simmons%2CBH&author=Lee%2CJH&author=Lalwani%2CK earning monthly?
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23443307 generate?
• How much money does http://scholar.google.com/scholar_lookup?&title=PI3K%20and%20MEK%20inhibitor%20combinations%3A%20examining%20the%20evidence%20in%20selected%20tumor%20types&journal=Cancer%20Chemother%20Pharmacol&doi=10.1007%2Fs00280-013-2121-1&volume=71&issue=6&pages=1395-1409&publication_year=2013&author=Britten%2CCD make?
• What are the earnings of https://doi.org/10.1371%2Fjournal.pone.0113037?
• Get to know what's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25401499
• What's the total monthly financial gain of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234626?
• How much does http://scholar.google.com/scholar_lookup?&title=Dual%20pharmacological%20targeting%20of%20the%20MAP%20kinase%20and%20PI3K%2FmTOR%20pathway%20in%20preclinical%20models%20of%20colorectal%20cancer&journal=PLoS%20One&doi=10.1371%2Fjournal.pone.0113037&volume=9&issue=11&publication_year=2014&author=Pitts%2CTM&author=Newton%2CTP&author=Bradshaw-Pierce%2CEL pull in?
• What are the total earnings of https://doi.org/10.1158%2F1078-0432.CCR-14-3377?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25977343 generate monthly?
• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558307 income
• How much income does http://scholar.google.com/scholar_lookup?&title=MEK%20inhibitor%20PD-0325901%20overcomes%20resistance%20to%20PI3K%2FmTOR%20inhibitor%20PF-5212384%20and%20potentiates%20antitumor%20effects%20in%20human%20head%20and%20neck%20squamous%20cell%20carcinoma&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-14-3377&volume=21&issue=17&pages=3946-3956&publication_year=2015&author=Mohan%2CS&author=Vander%20Broek%2CR&author=Shah%2CS have?
• https://doi.org/10.1177%2F1758834015571111's financial summary
• What are the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26673580?
• What are the total earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406912?
• How much profit does http://scholar.google.com/scholar_lookup?&title=MEK%20and%20PI3K%20inhibition%20in%20solid%20tumors%3A%20rationale%20and%20evidence%20to%20date&journal=Ther%20Adv%20Med%20Oncol&doi=10.1177%2F1758834015571111&volume=7&issue=3&pages=170-180&publication_year=2015&author=Jokinen%2CE&author=Koivunen%2CJP make?
• What are the earnings of https://doi.org/10.1158%2F1535-7163.MCT-11-0185?
• What is the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21750219?
• What's the revenue for http://scholar.google.com/scholar_lookup?&title=PF-04691502%2C%20a%20potent%20and%20selective%20oral%20inhibitor%20of%20PI3K%20and%20mTOR%20kinases%20with%20antitumor%20activity&journal=Mol%20Cancer%20Ther&doi=10.1158%2F1535-7163.MCT-11-0185&volume=10&issue=11&pages=2189-2199&publication_year=2011&author=Yuan%2CJ&author=Mehta%2CPP&author=Yin%2CMJ?
• Financial intake of http://scholar.google.com/scholar_lookup?&title=Phase%20I%20study%20of%20PF-04691502%2C%20a%20small-molecule%2C%20oral%2C%20dual%20inhibitor%20of%20PI3K%20and%20mTOR%2C%20in%20patients%20with%20advanced%20cancer&journal=Investig%20New%20Drugs&doi=10.1007%2Fs10637-013-0062-5&volume=32&issue=3&pages=510-517&publication_year=2014&author=Britten%2CCD&author=Adjei%2CAA&author=Millham%2CR
• How much does https://doi.org/10.1016%2Fj.ygyno.2016.04.019 bring in each month?
• How profitable is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27103175?
• How profitable is http://scholar.google.com/scholar_lookup?&title=A%20randomized%2C%20phase%20II%20non-comparative%20study%20of%20PF-04691502%20and%20gedatolisib%20%28PF-05212384%29%20in%20patients%20with%20recurrent%20endometrial%20cancer&journal=Gynecol%20Oncol&doi=10.1016%2Fj.ygyno.2016.04.019&volume=142&issue=1&pages=62-69&publication_year=2016&author=Campo%2CJM&author=Birrer%2CM&author=Davis%2CC?
• Learn how profitable https://doi.org/10.1158%2F1078-0432.CCR-10-1694 is on a monthly basis
• What's the financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21325073?
• How much does http://scholar.google.com/scholar_lookup?&title=Antitumor%20efficacy%20of%20PKI-587%2C%20a%20highly%20potent%20dual%20PI3K%2FmTOR%20kinase%20inhibitor&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-10-1694&volume=17&issue=10&pages=3193-3203&publication_year=2011&author=Mallon%2CR&author=Feldberg%2CLR&author=Lucas%2CJ earn?
• What's the monthly money flow for http://scholar.google.com/scholar_lookup?&title=A%20randomized%20phase%202%20study%20%28B2151005%29%20of%20PF-05212384%20plus%20irinotecan%20versus%20cetuximab%20plus%20irinotecan%20in%20patients%20with%20wild-type%20KRAS%20metastatic%20colorectal%20cancer&journal=J%20Clin%20Oncol&volume=32&issue=15%20suppl&publication_year=2014&author=Tabernero%2CJ&author=Brega%2CN&author=Davis%2CC?
• What is the earnings of https://doi.org/10.1158%2F1078-0432.CCR-14-1306?
• Revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25652454
• How much revenue does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508327 generate?
• Discover the revenue of http://scholar.google.com/scholar_lookup?&title=First-in-human%20study%20of%20PF-05212384%20%28PKI-587%29%2C%20a%20small-molecule%2C%20intravenous%2C%20dual%20inhibitor%20of%20PI3K%20and%20mTOR%20in%20patients%20with%20advanced%20cancer&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-14-1306&volume=21&issue=8&pages=1888-1895&publication_year=2015&author=Shapiro%2CGI&author=Bell-McGuinn%2CKM&author=Molina%2CJR
• What's the monthly income of https://doi.org/10.1158%2F1078-0432.CCR-09-1883?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20215549 earn?
• http://scholar.google.com/scholar_lookup?&title=Phase%20I%20pharmacokinetic%20and%20pharmacodynamic%20study%20of%20the%20oral%20MAPK%2FERK%20kinase%20inhibitor%20PD-0325901%20in%20patients%20with%20advanced%20cancers&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-09-1883&volume=16&issue=6&pages=1924-1937&publication_year=2010&author=LoRusso%2CPM&author=Krishnamurthi%2CSS&author=Rinehart%2CJJ's total income per month
• How much does https://doi.org/10.1158%2F1078-0432.CCR-09-1920 pull in?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20332327 pull in?
• Earnings of http://scholar.google.com/scholar_lookup?&title=A%20phase%20II%20study%20of%20PD-0325901%2C%20an%20oral%20MEK%20inhibitor%2C%20in%20previously%20treated%20patients%20with%20advanced%20non-small%20cell%20lung%20cancer&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-09-1920&volume=16&issue=8&pages=2450-2457&publication_year=2010&author=Haura%2CEB&author=Ricart%2CAD&author=Larson%2CTG
• Learn about the earnings of https://doi.org/10.1200%2FJCO.2007.12.0949
• What is the monthly revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17876013?
• http://scholar.google.com/scholar_lookup?&title=Randomized%20phase%20II%20trial%20of%20cetuximab%2C%20bevacizumab%2C%20and%20irinotecan%20compared%20with%20cetuximab%20and%20bevacizumab%20alone%20in%20irinotecan-refractory%20colorectal%20cancer%3A%20the%20BOND-2%20study&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2007.12.0949&volume=25&issue=29&pages=4557-4561&publication_year=2007&author=Saltz%2CLB&author=Lenz%2CHJ&author=Kindler%2CHL's total income per month
• How much revenue does https://doi.org/10.1200%2FJCO.2006.06.7595 generate?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17050875 make?
• What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Multicenter%20phase%20II%20and%20translational%20study%20of%20cetuximab%20in%20metastatic%20colorectal%20carcinoma%20refractory%20to%20irinotecan%2C%20oxaliplatin%2C%20and%20fluoropyrimidines&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2006.06.7595&volume=24&issue=30&pages=4914-4921&publication_year=2006&author=Lenz%2CH-J&author=Cutsem%2CE&author=Khambata-Ford%2CS?
• How much money does https://doi.org/10.1016%2Fj.celrep.2013.12.035 generate?
• How much income is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24440717 earning monthly?
• Check the income stats for http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409143
• How much profit is http://scholar.google.com/scholar_lookup?&title=Assessing%20PIK3CA%20and%20PTEN%20in%20early-phase%20trials%20with%20PI3K%2FAKT%2FmTOR%20inhibitors&journal=Cell%20Rep&doi=10.1016%2Fj.celrep.2013.12.035&volume=6&issue=2&pages=377-387&publication_year=2014&author=Janku%2CF&author=Hong%2CDS&author=Fu%2CS making per month?
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28357727's revenue stream
• Profit of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447332
• How much money does http://scholar.google.com/scholar_lookup?&title=A%20phase%20Ib%20study%20of%20the%20dual%20PI3K%2FmTOR%20inhibitor%20dactolisib%20%28BEZ235%29%20combined%20with%20everolimus%20in%20patients%20with%20advanced%20solid%20malignancies&journal=Target%20Oncol&doi=10.1007%2Fs11523-017-0482-9&volume=12&issue=3&pages=323-332&publication_year=2017&author=Wise-Draper%2CTM&author=Moorthy%2CG&author=Salkeni%2CMA generate?
• How much revenue does https://doi.org/10.1158%2F0008-5472.CAN-12-1726 produce monthly?
• What's the monthly money flow for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23066039?
• Financial intake of http://scholar.google.com/scholar_lookup?&title=PIK3CA%20mutation%20H1047R%20is%20associated%20with%20response%20to%20PI3K%2FAKT%2FmTOR%20signaling%20pathway%20inhibitors%20in%20early-phase%20clinical%20trials&journal=Cancer%20Res&doi=10.1158%2F0008-5472.CAN-12-1726&volume=73&issue=1&pages=276-284&publication_year=2013&author=Janku%2CF&author=Wheler%2CJJ&author=Naing%2CA
• See how much https://doi.org/10.1158%2F1078-0432.CCR-14-1814 makes per month
• What's the revenue for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25500057?
• What's the income generated by http://scholar.google.com/scholar_lookup?&title=A%20phase%20Ib%20dose-escalation%20study%20of%20the%20oral%20pan-PI3K%20inhibitor%20buparlisib%20%28BKM120%29%20in%20combination%20with%20the%20oral%20MEK1%2F2%20inhibitor%20trametinib%20%28GSK1120212%29%20in%20patients%20with%20selected%20advanced%20solid%20tumors&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-14-1814&volume=21&issue=4&pages=730-738&publication_year=2015&author=Bedard%2CPL&author=Tabernero%2CJ&author=Janku%2CF each month?
• http://scholar.google.com/scholar_lookup?&title=A%20phase%20Ib%20dose-escalation%20study%20of%20the%20MEK%20inhibitor%20trametinib%20in%20combination%20with%20the%20PI3K%2FmTOR%20inhibitor%20GSK2126458%20in%20patients%20with%20advanced%20solid%20tumors&journal=Investig%20New%20Drugs&doi=10.1007%2Fs10637-016-0377-0&volume=34&issue=6&pages=740-749&publication_year=2016&author=Grilley-Olson%2CJE&author=Bedard%2CPL&author=Fasolo%2CA's total income per month
• Check the income stats for https://doi.org/10.1158%2F1535-7163.MCT-12-0290
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22723336 rake in every month?
• How much profit is http://scholar.google.com/scholar_lookup?&title=Molecular%20profiling%20of%20patients%20with%20colorectal%20cancer%20and%20matched%20targeted%20therapy%20in%20phase%20I%20clinical%20trials&journal=Mol%20Cancer%20Ther&doi=10.1158%2F1535-7163.MCT-12-0290&volume=11&issue=9&pages=2062-2071&publication_year=2012&author=Dienstmann%2CR&author=Serpico%2CD&author=Rodon%2CJ making per month?
• Discover the revenue of https://doi.org/10.1158%2F1078-0432.CCR-13-2403
• Explore the financials of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24583798
• What is the earnings of http://scholar.google.com/scholar_lookup?&title=Phase%20I%20safety%2C%20pharmacokinetic%2C%20and%20pharmacodynamic%20study%20of%20SAR245409%20%28XL765%29%2C%20a%20novel%2C%20orally%20administered%20PI3K%2FmTOR%20inhibitor%20in%20patients%20with%20advanced%20solid%20tumors&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-13-2403&volume=20&issue=9&pages=2445-2456&publication_year=2014&author=Papadopoulos%2CKP&author=Tabernero%2CJ&author=Markman%2CB?
• What's http://scholar.google.com/scholar_lookup?&title=Phase%20I%20dose-escalation%20and%20-expansion%20study%20of%20buparlisib%20%28BKM120%29%2C%20an%20oral%20pan-class%20I%20PI3K%20inhibitor%2C%20in%20patients%20with%20advanced%20solid%20tumors&journal=Investig%20New%20Drugs&doi=10.1007%2Fs10637-014-0082-9&volume=32&issue=4&pages=670-681&publication_year=2014&author=Rodon%2CJ&author=Bra%C3%B1a%2CI&author=Siu%2CLL's gross income?
• https://citation-needed.springer.com/v2/references/10.1007/s11523-017-0530-5?format=refman&flavour=references's total income per month
• What's the financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Zev%20A.%20Wainberg?
• Income figures for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Zev%20A.%20Wainberg%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• Profit of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Maria%20Alsina
• Financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Maria%20Alsina%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• Get to know https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Heloisa%20P.%20Soares's earnings
• What's the financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Heloisa%20P.%20Soares%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Find out how much https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Irene%20Bra%C3%B1a earns monthly
• Financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Irene%20Bra%C3%B1a%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Carolyn%20D.%20Britten generate monthly?
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Carolyn%20D.%20Britten%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
• How much cash flow does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Gianluca%20Del%20Conte have monthly?
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Gianluca%20Del%20Conte%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en net monthly?
• How much profit is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Patrick%20Ezeh making per month?
• Revenue of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Patrick%20Ezeh%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• Check the income stats for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Brett%20Houk
• https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Brett%20Houk%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's revenue stream
• How much income does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kenneth%20A.%20Kern have?
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kenneth%20A.%20Kern%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Stephen%20Leong earn?
• What's the financial gain of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Stephen%20Leong%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Nuzhat%20Pathan generate monthly?
• Income figures for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Nuzhat%20Pathan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kristen%20J.%20Pierce earn?
• What's the financial gain of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kristen%20J.%20Pierce%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much income is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Lillian%20L.%20Siu earning monthly?
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Lillian%20L.%20Siu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en pull in monthly?
• Income figures for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jennifer%20Vermette
• Get to know what's the income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jennifer%20Vermette%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• Earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Josep%20Tabernero
• What's the financial gain of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Josep%20Tabernero%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• https://static-content.springer.com/esm/art%3A10.1007%2Fs11523-017-0530-5/MediaObjects/11523_2017_530_MOESM1_ESM.pdf's total income per month
• What's the income of https://s100.copyright.com/AppDispatchServlet?title=A%20Multi-Arm%20Phase%20I%20Study%20of%20the%20PI3K%2FmTOR%20Inhibitors%20PF-04691502%20and%20Gedatolisib%20%28PF-05212384%29%20plus%20Irinotecan%20or%20the%20MEK%20Inhibitor%20PD-0325901%20in%20Advanced%20Cancer&author=Zev%20A.%20Wainberg%20et%20al&contentID=10.1007%2Fs11523-017-0530-5©right=The%20Author%28s%29&publication=1776-2596&publicationDate=2017-10-24&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY-NC?
• Income figures for https://crossmark.crossref.org/dialog/?doi=10.1007/s11523-017-0530-5
• Find out how much https://citation-needed.springer.com/v2/references/10.1007/s11523-017-0530-5?format=refman&flavour=citation earns monthly
• What's the financial gain of https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral?
• Check the income stats for https://www.springernature.com/gp/products
• What's the income generated by https://www.springernature.com/gp/librarians each month?
• How much does https://www.springernature.com/gp/societies pull in?
• How much money does https://www.springernature.com/gp/partners generate?
• What's the financial outcome of https://www.springer.com/?
• How much profit does https://www.nature.com/ make?
• Get to know what's the income of https://www.biomedcentral.com/
• What's the monthly income of https://www.palgrave.com/?
• How much does https://www.apress.com/ pull in?
• Profit of https://www.springernature.com/gp/legal/ccpa
• How much does https://www.springernature.com/gp/info/accessibility rake in every month?
• What's the profit of https://support.springernature.com/en/support/home?
• How much does https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations make?
• What's the financial gain of https://www.springernature.com/?

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Clipboard.js
• Prism.js

CDN Services {📦}

• Crossref